In this study, we evaluated three novel drug classes in our Tsc2-/- subcutaneous tumor model: an enzyme that interferes with amino acid metabolism (asparaginase), two VEGF inhibitors (sunitinib and bevacizumab), and a microtubule inhibitor (vincristine). This evidence concerns the gene TSC2 and neoplasm.